P-TEV
Chronic Venous Insufficiency (CVI)
Phase 2/3Active
Key Facts
About VERIGRAFT
VERIGRAFT is a clinical-stage biotech pioneering a platform to create personalized, decellularized tissue grafts that are recellularized with the patient's own cells, potentially eliminating transplant rejection. The company is advancing a pipeline targeting chronic venous insufficiency (CVI), peripheral artery disease (PAD), nerve repair, and heart valve replacement, with its lead P-TEV program having reported first-in-human results. With a recent SEK 110 million capital commitment and a pivotal Phase II/III trial application submitted in Europe, VERIGRAFT is positioning to validate its technology in significant therapeutic areas with high unmet need.
View full company profile